Industry › Clinical Trials

Press Releases

Resilient Interim Results, Essex Bio-Technology Drives Growth and Innovation

Aug 26, 2025 20:00 HKT/SGT

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab)

Aug 25, 2025 18:30 HKT/SGT

Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle

Aug 20, 2025 20:30 HKT/SGT

CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers

Aug 19, 2025 16:00 JST

CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers

Aug 19, 2025 15:00 HKT/SGT

康哲药业（867.HK，8A8.SG）上半年营收净利双升战略转型跑出增长新动能

Aug 19, 2025 11:53 HKT/SGT

康哲藥業（867.HK，8A8.SG）上半年營收淨利雙升戰略轉型跑出增長新動能

Aug 19, 2025 11:53 HKT/SGT

UNFPA and NEC Collaborate to Build Beneficiary Information Management and e-Voucher System

Aug 18, 2025 13:38 HKT/SGT

NMPA已受理亿胜生物关于EB12-20145P（HLX04-O）用于治疗湿性年龄相关性黄斑变性的生物制品许可申请

Aug 13, 2025 21:25 HKT/SGT

NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration

Aug 13, 2025 20:24 HKT/SGT

NMPA已受理億勝生物關於EB12-20145P（HLX04-O）用於治療濕性年齡相關性黃斑變性的生物製品許可申請

Aug 13, 2025 20:24 HKT/SGT

Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC

Jul 31, 2025 08:30 HKT/SGT

New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease

Jul 31, 2025 08:20 HKT/SGT

Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

Jul 31, 2025 08:10 HKT/SGT

LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma

Jul 29, 2025 08:01 HKT/SGT

China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China

Jul 29, 2025 05:00 JST

China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China

Jul 29, 2025 04:00 HKT/SGT

Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China

Jul 25, 2025 11:52 JST

億勝生物多劑量地誇磷索鈉滴眼液獲中國國家藥品監督管理局批准上市

Jul 25, 2025 10:52 HKT/SGT

亿胜生物多剂量地夸磷索钠滴眼液获中国国家药品监督管理局批准上市

Jul 25, 2025 10:52 HKT/SGT